Lowest danger rate
在CNP类似物赛道，Ascendis的TransCon-CNP率先实现了剂型升级。与Vosoritide不一样的设计是TransCon-CNP被一层保护分子包裹，降低了体内清除影响，延长作用时间，实现每周一次给药。非头对头临床数据显示，TransCon-CNP每年2.29厘米的增高表现也优于Vosoritide。
。一键获取谷歌浏览器下载是该领域的重要参考
Chris BaraniukTechnology Reporter
Overall, I’m very sad at the state of agentic discourse but also very excited at its promise: it’s currently unclear which one is the stronger emotion.